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Activation of an oncogene via its juxtaposition to the IGH locus by a chromosomal translocation or, less frequently, by genomic
amplification is considered a major mechanism of B-cell lymphomagenesis. However, amplification of an IGH/oncogene fusion,
coined a complicon, is a rare event in human cancers and has been associated with poor outcome and resistance to treatment.
In this article are descriptions of two cases of germinal-center-derived B-cell lymphomas with IGH/BCL2 fusion that additionally
displayed amplification of an IGH/MYC fusion. As shown by fluorescence in situ hybridization, the first case contained a IGH/
MYC complicon in double minutes, whereas the second case showed a BCL2/IGH/MYC complicon on a der(8)t(8;14)t(14;18).
Additional molecular cytogenetic and mutation analyses revealed that the first case also contained a chromosomal transloca-
tion affecting the BCL6 oncogene and a biallelic inactivation of TP53. The second case harbored a duplication of REL and
acquired a translocation affecting IGL and a biallelic inactivation of TP53 during progression. Complicons affecting Igh/Myc have
been reported previously in lymphomas of mouse models simultaneously deficient in Tp53 and in genes of the nonhomologous
end–joining DNA repair pathway. To the best of our knowledge, this is the first time that IGH/MYC complicons have been
reported in human lymphomas. Our findings imply that the two mechanisms resulting in MYC deregulation, that is, transloca-
tion and amplification, can occur simultaneously. VC 2005 Wiley-Liss, Inc.
The translocation t(14;18)(q32;q21) is the cytoge-
netic hallmark of follicular lymphomas (FLs) but is
also recurrent in 15%–20% of de novo germinal
center–derived diffuse large B-cell lymphomas
(Cigudosa et al., 1999; Akasaka et al., 2000; Nath-
wani et al., 2001; Huang et al., 2002; Rosenwald
et al., 2002). This translocation juxtaposes the
BCL2 locus in 18q21 to regulatory elements of the
IGH locus in 14q32, leading to deregulated expres-
sion of the former. However, a t(14;18) is not
sufficient to induce malignant transformation, and
the acquisition of secondary genetic changes is
required for tumorigenesis (McDonnell and
Korsmeyer, 1991; Hoglund et al., 2004).
The clinical behavior of FL is indolent, with a 5-
year median survival of 72% (The Non-Hodgkin’s
Lymphoma Classification Project, 1997). About
30% of the FLs transform to a high-grade lym-
phoma. This histologic transformation, which usu-
ally is associated with rapidly progressing disease
and a fatal outcome (Nathwani et al., 2001), is char-
acterized by increased chromosomal instability and
the accumulation of secondary chromosomal chan-
ges. Among these secondary changes, various rear-
rangements of the MYC locus, at 8q24, leading to
deregulated expression of the MYC transcription
factor have been reported recurrently in high-grade
IGH/BCL2-positive lymphomas (Lee et al., 1989;
Thangavelu et al., 1990; Yano et al., 1992; Farrugia
et al., 1994; Macpherson et al., 1999; Lossos et al.,
2002). These chromosomal changes include, on
the one hand, chromosomal translocations juxta-
posing MYC with immunoglobulin (IG) and non-IG
loci, and on the other hand, genomic gains and
amplifications of 8q24, leading to an increased
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gene dosage of MYC. Remarkably, mice double-
transgenic for Igh/Bcl2 and Igh/Myc rapidly develop
lymphoid tumors, suggesting cooperation between
Bcl2 and Myc in the process of lymphomagenesis
(Strasser et al., 1990; Marin et al., 1995)
In this article, we describe two cases of clinically
aggressive IGH/BCL2-positive germinal-center
lymphomas with concurrent IGH/MYC fusion.
Remarkably, both cases showed genomic amplifica-
tions of the fused IGH/MYC loci. Such complex
rearrangements containing amplification of two loci
juxtaposed by a chromosomal translocation have
recently been designated as complicons by Zhu
et al. (2002). These and other authors reported
amplification of the Igh/Myc fusion in pro-B-cell
lymphomas arising in transgenic mice deficient in
the Tp53 gene and members of the non-homolo-
gous end–joining (NHEJ) DNA repair pathway
(Difilippantonio et al., 2002; Zhu et al., 2002;
Gladdy et al., 2003; reviewed in Mills et al., 2003).
Mechanistically, complicons imply two alterna-
tive genomic means of MYC deregulation—translo-
cation and amplification—to act simultaneously on
the very same allele. To the best of our knowledge,
such complicons containing IGH/MYC fusions have
not yet been reported in human lymphomas.
Case 1. A 40-year-old man presented with a
3-week history of fever and night sweats. Physical
examination revealed cervical lymphadenopathy,
hepatosplenomegaly, and an epigastric mass. Mor-
phologic analyses of bone marrow and gall bladder
biopsy specimens were diagnostic for diffuse large
B-cell lymphoma (DLBCL) according to the
WHO classification. Immunophenotypic analyses
of these biopsy specimens, performed with flow
cytometry and immunohistochemistry, revealed
the tumor clone to be positive for CD10, CD19,
CD20, CD38, CD45, CD79a, HLA-DR, sIgKappa,
Ki-67 (95%), BCL2, and BCL6 and negative for
CD3, CD22, CD33, CD34, CD177, cMPO, FMC7,
and sIglambda (Table 1). The bone marrow biopsy
displayed two small paratrabecular foci with mor-
phologic features characteristic of FL, suggesting
the diagnosis of a secondary aggressive DLBCL
transformed from clinically occult FL. The patient
was treated with anthracycline-containing polyche-
motherapy (protocol BFM-86) and achieved a par-
tial remission after the first treatment cycle. The
clinical course was complicated by septicemia from
gram-negative bacteria, from which the patient
succumbed 2 months after the initial diagnosis.
The family history was uneventful. Clinical and
laboratory parameters are listed in Table 1.
Case 2. A 28-year-old man presented with gen-
eral discomfort and multiple sites of lymphadenop-
athy on both sides of the diaphragm. The morpho-
logic examination of a lymph node biopsy speci-
men was compatible with a diagnosis of FL, grade
II. Immunohistochemical analyses from the same
specimen revealed the tumor clone to be positive
for CD10, CD20, CD45RA, Ki-67 (50–60%),
BCL2, and BCL6 and negative for CD5, CD43,
and CD45RO (Table 1). A simultaneous bone mar-
row biopsy showed a Burkitt-like lymphoma. The
patient was treated with 8 cycles according to the
CHOP protocol. Nine months after the initial diag-
nosis, still during evaluation of the treatment
response, CT scan revealed a large abdominal
mass, and a biopsy revealed an FL, grade III. Fur-
ther chemotherapeutic regimens induced only lim-
ited responses. The patient died 16 months after
the initial diagnosis as a result of progressive dis-
ease. The family history was unremarkable. Clini-
cal and laboratory parameters are listed in Table 1.
Conventional cytogenetic analyses of G-banded
chromosomes from bone marrow specimens
revealed complex karyotypes in both cases. In case
1, the karyotype was near-triploid, with additions
of unknown origin, marker chromosomes, and mul-
tiple double minutes (dmins). Spectral karyotyping
(SKY) in this case, performed as described recently
(Cigudosa et al., 2003), revealed a t(2;3)(q21;q27),
a t(14;18)(q32;q21), and a der(17)t(4;8;17)(?;q24?;
p11.2) as well as multiple double minutes and
aneusomies (Table 1). In case 2, the G-banding
karyotype at diagnosis was hyperdiploid, with sev-
eral unresolved chromosomal changes (Table 1).
After 9 and 14 months from the time of initial diag-
nosis, cytogenetic analysis of a second and third
bone marrow sample, respectively, showed several
additional chromosomal alterations, indicating clo-
nal evolution (Table 1). SKY, performed in the
sample at progression (14 months after diagnosis),
identified t(3;22)(q27;q11.2), der(8)t(8;18)(q24;q?)
hsr(8)(q24), der(14)t(14;16)(q32;q?), and der(17)t(7;
16;17)(?;?;p11.2) and indicated the presence of
complex rearrangements including homogeneously
staining regions (hsrs) on chromosome arms 1q, 2p,
and 8q (Table 1). The der(8)t(8;18)(q24;q?)
hsr(8)(q24) was already present at diagnosis and
was initially described as an add(8q24) by G-band-
ing analysis.
Considering the chromosomal complexity in
both cases, multiple metaphase and interphase
FISH analyses were performed for further cyto-
genetic characterization (Tables 1 and 2), apply-
ing previously published protocols (Martin-Subero
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et al., 2002a, 2002c). FISH with the LSI IGH/
BCL2 probe indicated the presence of an IGH/
BCL2 juxtaposition in both patients. Interestingly,
case 1 displayed massive amplification of the
hybridization signals for the IGH locus in multiple
dmins, whereas case 2 displayed triplication in tan-
dem with the IGH/BCL2 juxtaposed signals on the
derivative chromosome der(8) (Table 2). Molecular
genetic analyses based on PCR demonstrated the
presence of an IGH/BCL2 fusion (in the major
breakpoint region of BCL2, MBR) in patient 1,
whereas in case 2, this molecular analysis was nega-
tive for MBR and minor cluster region breakpoints,
although the sample was IGH/BCL2-positive by
FISH. This finding is not surprising because sys-
tematic studies comparing different methods of
detecting the IGH/BCL2 fusion have shown FISH
to be more reliable than molecular genetic
approaches (Poetsch et al., 1996; van Dongen
et al., 2003).
In case 1, FISH with the LSI IGH/MYC probe
revealed amplification of the IGH/MYC fusion sig-
nals in the dmins. To characterize the composition
of the complicon, a number of DNA probes span-
ning or flanking the MYC locus were applied as
well as a triple-color probe for IGH covering the
variable and constant sequences and the IGH prox-
imal region. The amplification in dmins was shown
to contain signals for the probes spanning/proximal
to MYC (Fig. 1A), and spanning the IGH constant
region (labeled in blue; Fig. 1B, Table 2). Addi-
tional molecular cytogenetic analyses (summarized
in Table 1) indicated the presence of a transloca-
tion affecting the BCL6 locus (Fig. 1C) and a dele-
tion of the TP53 gene (Fig. 1D). Deletion of the
TP53 gene is a well-established marker of a poor
prognosis in germinal center B-cell lymphoma
(Farrugia et al., 1994; Tilly et al., 1994).
To determine whether the remaining allele also
was inactivated, mutation screening of exons 2–11
of TP53 was performed by direct sequencing using
previously reported PCR conditions and primers
(Agirre et al., 2002). This analysis indicated a 2-bp
deletion in codon 209 of exon 6, leading to a stop
TABLE 2. Composition of Complicons on the dmin in Case 1 and on the Derivative Chromosome der(8) in Case 2
(based on FISH to metaphase cells)
FISH probe
Source/reference of
the FISH probes
Double minutes
in patient 1
der(8) in
patient 2
LSI IGH/MYC, CEP8 Vysis/Abbott, Downers Grove, IL IGH/MYC fusion
amplified
IGH/MYC fusion
2–3 copies
LSI IGH/BCL2 Vysis/Abbott, Downers Grove, IL IGH amplified IGH/BCL2 fusion
2–3 copies
LSI IGH/BCL2 þ MYC Vysis/Abbott, Downers Grove, IL
MYC cosmids: Siebert et al., 1998
IGH/MYC fusion
amplified
BCL2/IGH/MYC fusion
2–3 copies
LSI MYC Vysis/Abbott, Downers Grove, IL only centromeric
signal amplified
only centromeric
signal 2–3 copies
RP11-1136L8 (proximal
to MYC)
RPCI11 BAC library* amplified 2–3 copies
CTD-3056O22
(spanning MYC)
CTD BAC library* amplified 2–3 copies
CTD-2267H22 (distal
to MYC)
CTD BAC library* not present not present
Triple color IGH LSI IGH þ
RP11-417P24
Vysis/Abbott, DG, II;
RPCI11 BAC library*
only signals for the
IGH constant
region amplified
only signals for the
IGH constant
region 2–3 copies
BCL2 (RP11-13L22/RP11-
215A20-centromeric þ
RP11-635N19/RP11-
851B10-telomeric)
RPCI11 BAC library* not present only telomeric signal
2–3 copies
LSI BCL6 Vysis/Abbott, Downers Grove, IL not present not present
LSI ATM/P53/CEP17 Vysis/Abbott, Downers Grove, IL not present not present
IGK Martin-Subero et al., 2002c not present not present
IGL Martin-Subero et al., 2002c not present not present
REL (RP11-625B6 telomeric/
RP11-91218 centromeric)
RPCI11 BAC library* not present not present
BCL3 Martin-Subero et al.,
manuscript in preparation
not present not present
*BAC clones were obtained from Research Genetics/Invitrogen (http://mp.invitrogen.com/), the German Resource Center for Genome Research
(http://www.rzpd.de/), or the Sanger Centre (http://www.sanger.ac.uk/).
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Figure 1. (A–D) FISH analyses of case 1. (A) Interphase and meta-
phase nuclei hybridized with the LSI MYC breakapart probe (Vysis,
Downers Grove, IL). Six nuclei show high-level amplification of the cen-
tromeric MYC probe (labeled in red), whereas one nucleus displays a
regular signal constellation, that is, two colocalized red/green signals
(arrow). The metaphase shows the amplified MYC sequences to be
located in double-minute (dmin) chromosomes. (B) Metaphase cell
hybridized with the IGH triple-color probe. Chromosomes containing
triple red/green/pale blue colocalizations indicate the presence of an
intact IGH locus (arrows). Chromosomes with sequences centromeric
to IGH (red) and spanning the IGH constant region (pale blue) point to
der(14)(q32) from a translocation affecting IGH (arrowheads). Blue sig-
nals mapping to extrachromosomal elements indicate that the dmin
contain sequences from the IGH constant region. (C) Metaphase cell
hybridized with the LSI BCL6 breakapart probe (Vysis, Downers Grove,
IL), showing two each of isolated red and green signals (arrows), indi-
cating a translocation affecting BCL6 and two colocalized red/green sig-
nals pointing to an intact BCL6 locus. Dmin chromosomes are not visi-
ble with DAPI staining. (D) Interphase nuclei hybridized with the three-
color LSI ATM (green)/TP53 (red)/CEP17 (chromosome enumeration
probe, pale blue) probe (Vysis, Downers Grove, IL). The large nucleus
on the right-hand side contains three copies of ATM, two copies of
TP53, and four of the centromere of chromosome 17, pointing to a
deletion of the TP53 gene. In contrast, the small nucleus on the left-
hand side displays the regular signal pattern, that is, two signals for each
locus. (E–F) Sequence analysis of TP53 exon 6 in case 1. (E) Wild-type
sequence. (F) Sequence from case 1 showing a 2-bp deletion (AG) cor-
responding to the 209 codon (AGA) of the TP53 gene. (G–J) FISH analy-
ses of case 2. (G–I) Partial metaphase cells hybridized with (G) the LSI
MYC breakapart probe (Vysis, Downers Grove, IL) and the triple-color
probes for (H) IGH and (I) BCL2 (red)/IGH (green)/MYC (pale blue). The
derivative chromosome der(8) contains three copies in tandem of the
signals centromeric to (G) MYC (red) and spanning the (H) IGH con-
stant region (pale blue) and (I) a triple fusion of the BCL2, IGH, and MYC
loci. (J) Interphase nucleus hybridized with the LSI ATM/P53/CEP17
probe (Vysis, Downers Grove, IL) showing two copies of ATM, one of
TP53, and two of CEP17, indicating that one allele of the TP53 gene is
deleted. (K–L) Sequence analysis of TP53 exon 9 in case 2. (K) Sequence
from case 2 at diagnosis showing the wild-type sequence. (L) Sequence
from case 2 in transformation showing a nonsense mutation in codon
331 (CAG?TAG) of the TP53 gene. (M–N) Metaphase cells hybridized
with a PNA probe for all human telomeres. (M) Metaphase cell from
case 1 showing multiple chromosome ends lacking detectable hybridiza-
tion signals (asterisks). Dmin chromosomes are not visible because of
their faint DAPI staining, but they clearly lack telomeric signals. (N)
Metaphase cell from case 2 showing all chromosome ends to contain
telomeric hybridization signals.
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six codons downstream (Fig. 1E and F). Conse-
quently, the function of the TP53 gene in this
patient was shown to be abolished in the tumor
cells. With regard to the translocation targeting
BCL6 detected by FISH, SKY pointed to chromo-
some band 2q21 as the translocation partner, a rear-
rangement that has been described previously
(Chen et al., 1998a). This finding indicates a BCL6
promoter substitution from a non-IG locus as a
translocation partner of BCL6, a common phenom-
enon in DLBCL (Chen et al., 1998b).
In case 2, FISH with the LSI IGH/MYC probe
at diagnosis revealed the presence of a triplication
of the fused IGH/MYC allele on the derivative
chromosome der(8). Considering the presence of
an IGH/BCL2 amplification in the same chromo-
some, this finding suggested a complicon involv-
ing a BCL2/IGH/MYC triple juxtaposition, which
was confirmed by three-color FISH (Fig. 1I,
Table 2).
Complex chromosomal translocations leading to
concurrent translocation of the BCL2 and MYC loci
to the same IGH allele has been described previ-
ously in transforming FL. In those cases, the BCL2
gene was shown to be juxtaposed next to IGH as a
result of an illegitimate V(D)J rearrangement,
whereas the MYC locus was fused to the already
translocated IGH/BCL2 allele because of a defec-
tive class switch rearrangement (Dyer et al., 1996).
Similarly to patient 1, hybridization with probes
flanking or spanning the MYC locus and the triple
probe for IGH showed that only the signals proxi-
mal/spanning the MYC locus (Fig. 1G) and the sig-
nals spanning the IGH constant region (Fig. 1H)
were present in der(8) (Table 2). Additional molec-
ular cytogenetics in metaphase nuclei from the
bone marrow sample at diagnosis from patient 2
(summarized in Table 1) indicated the presence of
an intrachromosomal duplication in 2p, including
the IGK and REL loci.
Chromosomal gain of 2p has been suggested to
confer a poor prognosis in B-NHLs (Yunis et al.,
1989) and is a common finding in transforming FL,
germinal-center-type DLBCL, and Hodgkin lym-
phoma (Joos et al., 2002; Martin-Subero et al.,
2002b; Rosenwald et al., 2002; Martı´nez-Climent
et al., 2003). Amplification in tandem of the BCL2/
IGH/MYC loci as well as duplication targeting the
REL locus also were detected in the sample after
transformation. Moreover, in the sample after
transformation, FISH provided evidence of dele-
tion of the TP53 gene (Fig. 1J) and translocation
with a breakpoint in the IGL locus, which were not
present at diagnosis and, thus, were acquired dur-
ing tumor progression. Results are shown in
Table 1.
Mutation analysis of exons 2–11 of the TP53
gene was performed in the samples at diagnosis
and at transformation. This analysis revealed a
nonsense mutation in codon 331 (CAG?TAG;
Gln?Stop) in exon 9, but only in the sample at
transformation. In addition, in the sample at diag-
nosis, two silent heterozygous polymorphisms were
detected, in codon 213 (CGA?CGG; Arg?Arg) of
exon 6 and in codon 264 (CTA?TTA; Leu?Leu)
of exon 8. In the sample at transformation, only the
CGA and CTA sequences were identified, indicat-
ing that the allele containing the CGG and TTA
sequences was the one lost as a result of chromoso-
mal deletion.
With regard to the translocation involving IGL in
22q11, cytogenetic analysis performed by SKY
indicated band 3q27 as the translocation partner.
However, although BCL6 was the most likely can-
didate partner, FISH on metaphase cells with a
breakapart probe (from Vysis/Abbott, Downers
Grove, IL) demonstrated that the breakpoint was
telomeric to BCL6. This might point to the pres-
ence of an alternative breakpoint region targeting
BCL6 that has been described as being 200–270 Kb
telomeric to the gene (Chen et al., 1998a) and
might therefore remain undetected with the
applied FISH probe, which spans 300 Kb telomeric
to the BCL6 locus (http://www.vysis.com). Another
hypothesis is that this translocation targets another
oncogene locus telomeric to BCL6.
To the best of our knowledge, this is the first
time that complicons affecting IGH/MYC have
been described in human malignant lymphomas.
Several recent reports have shown that transgenic
mice deficient both in Tp53 and in genes involved
in the NHEJ pathway (Ku70, Xrcc5 (Ku80), Xrcc4,
Dna-pk, and Dna Ligase IV) developed pro-B-cell
lymphomas that frequently displayed the nonreci-
procal translocation C12;15 (Igh on mouse chromo-
some 12 andMyc on mouse chromosome 15; C indi-
cates the chromosome containing the centromere)
with genomic amplification of the Igh/Myc fusion
(Difilippantonio et al., 2002; Zhu et al., 2002;
Gladdy et al., 2003; reviewed in Mills et al., 2003).
These studies proposed a model in which compli-
cons arose from several cycles of chromosome
breakage and fusion that eventually finished with
telomere capture from a different chromosome, sta-
bilizing the derivative chromosome. In support of
this hypothesis, the authors provided cytogenetic
evidence of both dicentric chromosomes and chro-
mosome tips lacking telomeric sequences that rep-
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resent intermediates of the breakage-fusion-bridge
model leading to complicons.
In light of these new findings and considering
the striking cytogenetic similarity between the
above-noted animal models and the two cases
described in this article, it is tempting to speculate
that a similar mechanism might have taken place
in the patients reported. However, this hypothesis
is difficult to prove because all clonal metaphase
cells studied by G-banding in both patients already
were very complex but without evidence of unsta-
ble dicentric chromosomes. Thus, the intermediate
steps in the generation of the complicons could not
be studied. Nevertheless, we applied a telomere
sequence–specific peptide nucleic acid probe
(PNA; DAKO, Glostrup, Denmark) to determine
the status of the telomeres in the two cases. The
cutoff for missing telomeres, calculated as the
mean of chromosome tips lacking telomeric
hybridization signals plus 3 times the standard
deviation of five metaphase cells each from five
healthy donors, was determined as 3.1%. Five
tumor metaphase cells from each case (case 1 at
diagnosis and case 2 at progression) were evaluated
for the signals derived from the PNA-telomere
probe. In the tumor metaphases of case 1, 6.4%
(range: 4.0%–8.3%) of the chromosome tips lacked
detectable hybridization signals (Fig. 1M), whereas
the tumor metaphase cells of case 2 showed intact
telomere sequences in all chromosomes (Fig. 1N).
Whether the lack of detectable telomeres in case
1 is directly or indirectly related to the generation
of the IGH/MYC complicon itself is unknown, but
it seems likely that it might promote increased
chromosomal instability. The dmin chromosomes
in case 1 did not show any detectable hybridization
signals with the PNA-telomere probe.
In case 2, a three-step rearrangement might have
taken place as an alternative to a process of itera-
tive breakage-fusion-bridge. According to this sec-
ond model, a defective V(D)J rearrangement lead-
ing to a t(14;18) with IGH/BCL2 fusion would be
followed by a defective switch rearrangement to
8q24, leading to a BCL2/IGH/MYC triple fusion.
Finally, a sequential unequal sister chromatid
exchange would occur, leading to the hsr on der(8).
In support of this model, the der(8)t(8;14)t(14;18)
telomere belonged to chromosome 18 according to
the SKY analysis, and therefore a telomere capture
event seems unlikely. Interestingly, TP53 was
shown to be completely inactivated (by mutation
and deletion) in this case, but only in the sample in
transformation. As the sample at diagnosis already
contained the complicon, the BCL2/IGH/MYC
amplification either arose independently of TP53
inactivation, or TP53 was inactivated by other
means. Remarkably, recent evidence suggests that
the BCL6 protein represses TP53 transcription in
germinal-center B cells (Phan and Dalla-Favera,
2004). Both cases in the present study expressed
TABLE 3. Overview of the 17p/TP53 Status in Published Hematologic Tumors Containing Complicons
Case/Reference Diagnosis
Organization
of complicon
17p/TP53 Status at the moment when
the complicon was detected
Case 1 in present report DLBCL MYC/IGH in dmins TP53 inactive (deletion and mutation)
Case 2 in present report (FL) FL BCL2/IGH/MYC in hsr TP53 intact (but most likely inactivated
by BCL6 expression)
Case 1 in Gruszka-Westwood
et al., 2002
MCL CCNDI/IGH in hsr TP53 inactive (deletion and mutation)
Case 1 in Metzke-Heidemann
et al., 2001
CML in BC BCR/ABL in hsr 17p13 deletion by der(17)
Case 2 in Metzke-Heidemann
et al., 2001
CML in BC BCR/ABL in hsr 17p13 deletion by add(17p)
Case 1 in Morel et al.,
2003 (CML)
CML in
megakaryoblastic
crisis
BCR/ABL in dmins 17p13 deletion by add(17p)
Case 1 in Campbell et al.,
2002 (CML)
CML in myeloid BC BCR/ABL in hsr 17p13 deletion by add(17p)
Case 2 in Campbell et al.,
2002 (CML)
CML in myeloid BC BCR/ABL in hsr 17p13 deletion by 17
Case 1 in Gargallo et al.,
2003
CML in myeloid BC BCR/ABL in hsr Complex karyotype without
cytogenetically detectable del(17p)
K-562 cell line in Rodley
et al., 1997
CML in BC BCR/ABL in hsr TP53 inactive (deletion and mutation)
DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; CML: chronic myeloid leukemia; BC: blast crisis; dmins:
double minutes; hsr: homogeneously staining region.
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BCL6 in the tumor cells at diagnosis, as shown by
immunohistochemistry (Table 1). Thus, TP53 ex-
pression is likely to be functionally inactivated in
the tumor cells of both cases.
Complicons affecting genes other than IGH/
MYC have been reported rarely in hematologic
malignancies and are associated with a poor out-
come and chromosomal complexity. Recently,
Gruszka-Westwood et al. (2002) described a clini-
cally aggressive case of leukemic mantle cell lym-
phoma with an IGH/CCND1 complicon. In chronic
myelogenous leukemia (CML), BCR/ABL compli-
cons have been described repeatedly as a mecha-
nism of disease progression and resistance to treat-
ment with STI-571 (Gorre et al., 2001; Metzke-
Heidemann et al., 2001; Morel et al., 2003). Most
interestingly, when the complicon was detected in
most hematologic disorders for which cytogenetic
data have been published as well as in one of the
cases presented here, a deletion of 17p13, the site
of the tumor-suppressor gene TP53, was detected
(Table 3). All the CMLs contained a classical
t(9;22)(q34;q11) at diagnosis and acquired a TP53
deletion and a BCR/ABL complicon in blastic crisis,
indicating that TP53 might also play an important
role in the development of BCR/ABL complicons.
Remarkably, NHEJ-deficient mice acquire compli-
cons only in the context of Tp53 inactivation,
which supports the hypothesis that complicons in
human hematologic cancers also might arise from
defective NHEJ DNA repair.
In the two cases reported here, no apparent cyto-
genetic changes were detected in the chromosomal
bands that are the sites of KU70 (22q13), KU80
(2q35), XRCC4 (5q14), DNAPK (8q11), and LIG4
(13q33) (Table 1).
Despite the inconclusive findings regarding the
mechanics of generating IGH/MYC complicons in
the two cases reported here, the marked similarity
of the mouse models reported by Zhu et al. (2002),
Difilippantonio et al. (2002), and Gladdy et al.
(2003) with the two cases presented in this report
warrants further investigation of the molecular sta-
tus of genes involved in the NHEJ DNA repair
pathway.
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